Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
Withdrawn before enrolling · Phase 2
Conditions studied: Carcinoma of Unknown Primary
In brief
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, docetaxel, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel and capecitabine works in treating patients with cancer of unknown primary origin.
Key facts
- Study ID
- NCT00119314
- Run by
- University of Medicine and Dentistry of New Jersey
- People needed
- 0
- Starts
- 2004-07-01
- Expected to finish
- 2005-07-01
- Last updated by the study team
- 2015-05-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cancer Institute of New Jersey at Hamilton — Hamilton, New Jersey, United States
- Cancer Center at the Mountainside Hospital — Montclair, New Jersey, United States
- Carol G. Simon Cancer Center at Morristown Memorial Hospital — Morristown, New Jersey, United States
- Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School — New Brunswick, New Jersey, United States
- Hematology and Oncology Group — Somerset, New Jersey, United States
- Overlook Hospital — Summit, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.